Pidilizumab
Based on 1 Customer Validation
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.00%
- CAS No.: 1036730-42-3
- Masse moléculaire:144.626 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9903
NivolumabPD-1 Inhibitor -
HY-P99052
TislelizumabPD-1 Inhibitor -
HY-P9978
ToripalimabPD-1 Inhibitor -
HY-P99048
SintilimabPD-1/PD-L1 Inhibitor -
HY-P9971
CamrelizumabPD-1 Neutralizing Antibody -
HY-P99203
CemiplimabPD-1 Inhibitor -
HY-P99118
SerplulimabAnti-PD-1 Antibody -
HY-P99108
PenpulimabAnti-PD-1 Monoclonal Antibody -
HY-P99941
Retifanlimabanti-PD-1 mAb -
HY-P9972
SpartalizumabPD-1 IgG4 Monoclonal Antibody -
HY-19745
BMS-202
Activité biologique
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PDCD1/PD-1/CD279
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1036730-42-3
-
Appearance Liquid
-
Masse moléculaire 144.626 kDa
-
Color Colorless to light yellow
-
SMILES
[Pidilizumab]
-
Synonyms
CT-011; MDV9300
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (255 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [Content Brief]
[2]. Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pidilizumab Related Classifications
HY-P990077 Related Classifications
Powered by Bioz